Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8067451 | HORIZON | Methods and medicaments for administration of ibuprofen |
Jul, 2026
(2 years from now) | |
US8309127 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) | |
US8449910 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) | |
US8318202 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) | |
US8501228 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) |
Drugs and Companies using FAMOTIDINE; IBUPROFEN ingredient
Market Authorisation Date: 23 April, 2011
Treatment: Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9168304 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US9132110 | HORIZON | Treatment of pain with topical diclofenac |
Oct, 2027
(3 years from now) | |
US9168305 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US9066913 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US9339551 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US9220784 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US9339552 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US9539335 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US8563613 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US8871809 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US9101591 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
US8252838 | HORIZON | Diclofenac topical formulation |
Apr, 2028
(4 years from now) | |
US8217078 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
US9415029 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
US9370501 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
US8618164 | HORIZON | Treatment of pain with topical diclofenac compounds |
Jul, 2029
(5 years from now) | |
US8741956 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
US9375412 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
US8546450 | HORIZON | Treatment of pain with topical diclofenac compounds |
Aug, 2030
(6 years from now) |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 16 January, 2014
Treatment: Use of topical diclofenac for treating pain; Use of topical diclofenac sodium for treating pain; Use of topical diclofenac on a joint for treating osteoarthritis; Use of topical diclofenac on the knee...
Dosage: SOLUTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9925157 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
US9925156 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
US9925158 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9192590 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
US9198882 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
US9925158 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
US9925157 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
US9925156 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
US9198882 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
US9192590 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
US8026284 | HORIZON | Enterically coated cystamine, cysteamine and derivatives thereof |
Sep, 2027
(3 years from now) | |
US8026284 (Pediatric) | HORIZON | Enterically coated cystamine, cysteamine and derivatives thereof |
Mar, 2028
(3 years from now) | |
US9173851 | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(10 years from now) | |
US9233077 | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(10 years from now) | |
US9173851 (Pediatric) | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(10 years from now) | |
US9233077 (Pediatric) | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(10 years from now) | |
US10905662 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
US10548859 | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
US10328037 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
US10143665 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
US10905662 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
US10328037 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
US10143665 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
US10548859 (Pediatric) | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 22, 2024 |
Pediatric Exclusivity (PED) | Jun 22, 2025 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 30 April, 2013
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9040085 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(24 days from now) | |
US8309124 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(24 days from now) | |
US8394407 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(24 days from now) | |
US9186332 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(24 days from now) | |
US9504699 | HORIZON | Delayed-release glucocorticoid treatment of rheumatoid disease |
Aug, 2027
(3 years from now) | |
US8168218 | HORIZON | Delayed release tablet with defined core geometry |
Jan, 2028
(3 years from now) |
Drugs and Companies using PREDNISONE ingredient
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet; ...
Dosage: TABLET, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8852636 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 9 months ago) | |
US8858996 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
May, 2022
(1 year, 9 months ago) | |
US9345695 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 9 months ago) | |
US9198888 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 9 months ago) | |
US9707181 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 9 months ago) | |
US9161920 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 9 months ago) | |
US9393208 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Sep, 2029
(5 years from now) | |
US9220698 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Mar, 2031
(6 years from now) | |
US8945621 | HORIZON | Method for treating a patient at risk for developing an NSAID-associated ulcer |
Oct, 2031
(7 years from now) |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient
Market Authorisation Date: 30 April, 2010
Treatment: Relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer; Risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment; Risk-reduction o...
Dosage: TABLET, DELAYED RELEASE;ORAL